论文部分内容阅读
肿瘤抗原是肿瘤免疫中的核心问题,待别是在肿瘤疫苗的研制过程中,面临的首要问题是需要具有免疫原性的抗原.如何制备肿瘤抗原和估价肿瘤抗原免疫原性是制备肿瘤疫苗过程中亟待解决的问题,为此,我们提取了卵巢癌细胞的可溶性成分,用这种物质在体外先后两次刺激正常人外周血单个核细胞(PBMC),能够使其活化、增殖、分泌淋巴因子(TNF,INF),而只用抗原进行一次刺激时,则不能使PBMC活化、增殖和分泌淋巴因子,从而确定这种提取物具有免疫原性.提取这种卵巢癌细胞DNA、RNA、热休克蛋白(HSP)、膜蛋白、多肽等成分进行进一步的免疫原性分析发现:膜蛋白和多肽具有免疫原性.
Tumor antigen is the core problem in tumor immunity. It is not the first problem that is faced in the development of a tumor vaccine that requires immunogenic antigens. How to prepare tumor antigens and evaluate the immunogenicity of tumor antigens is to prepare tumor vaccines. In order to solve the problem, we extracted the soluble components of ovarian cancer cells and used it to stimulate normal human peripheral blood mononuclear cells (PBMC) twice in vitro to activate, proliferate, and secrete lymphokines. (TNF, INF), but only once stimulated with the antigen, can not make PBMC activation, proliferation and secretion of lymphokines, thus confirming that this extract is immunogenic. Extraction of this ovarian cancer DNA, RNA, heat shock Proteins (HSP), membrane proteins, peptides and other components for further immunogenicity analysis found that: membrane proteins and peptides are immunogenic.